TTE

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Retrieved on: 
Sunday, April 7, 2024
Health, Sports, Football, Other Health, Other Science, Research, Science, Blood pressure, TTE, FACC, African Americans, Prevalence, Aortic stenosis, National Football League, Patient, Education, Ageing, Journal, History, MD, City, Male, American College, TAVR, EKG, AFL, Interventional cardiology, Alumni association, NFL, National Football League Alumni, Hypertension, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.
  • Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
  • Conducted across eight U.S. cities in cooperation with NFL Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE was a cross sectional study of NFL alumni and their family members aged 50 years and above.
  • Study participants self-reported their medical histories and participated in heart health education and screenings that included blood pressure, electrocardiogram (EKG) and echocardiogram.

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

Retrieved on: 
Sunday, April 7, 2024
Technology, Medical Devices, Surgery, Health Technology, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Diagnosis, TTE, Machine learning, Cardiovascular disease, Coronary artery disease, Pulmonary hypertension, Patient, Heart, Heart failure, American College, Data collection, FDA, CAD

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.

Key Points: 
  • The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.
  • Timely identification of left ventricular dysfunction plays a pivotal role in effective heart failure management, however, measuring elevated LVEDP currently relies on invasive left heart catheterization.
  • Sc.D., Executive Vice President and Chief Scientific Officer, CorVista Health.
  • “We believe the CorVista System can uniquely and effectively address these important unmet needs for people living with cardiovascular disease, especially in rural and underserved populations.”

CorVista Health Announces AHA Presentation of Machine Learning to Detect Pulmonary Hypertension at Point-of-Care

Retrieved on: 
Sunday, November 12, 2023
Women, Seniors, Parenting, Research, Software, Family, Consumer, Science, Social Media, Technology, Search Engine Optimization, Search Engine Marketing, Cardiology, Blogging, General Health, Publishing, Public Relations, Investor Relations, Health, Communications, Machine learning, Disease, Heart, AUC, Pulmonary hypertension, Point, AHA, Mortality, Cardiovascular disease, Patient, Multimedia, TTE, Echocardiography, FDA, Orthostatic hypertension, Point of care, Heart failure, Coronary artery disease, PPG, Diagnosis, Learning, PAH, OVG, HIV disease progression rates, Pharmaceutical industry

CorVista Health AHA Presentation--Machine Learning to Detect Pulmonary Hypertension at Point of Care. Presented by Dr. Charles Bridges. (Photo: Business Wire)

Key Points: 
  • CorVista Health, Inc. , a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the presentation of Machine Learning to Detect Pulmonary Hypertension data at AHA.
  • View the full release here: https://www.businesswire.com/news/home/20231112489250/en/
    CorVista Health AHA Presentation--Machine Learning to Detect Pulmonary Hypertension at Point of Care.
  • (Photo: Business Wire)
    “We are pleased to present this important data at this year’s AHA meeting.” said Don Crawford, President and CEO of CorVista Health.
  • “We believe the CorVista System® can make a tremendous impact to patients suffering from pulmonary hypertension, especially in rural and underserved populations.”

Peak Energy Appoints Chief Executive Officer and Chief Operating Officer

Retrieved on: 
Tuesday, October 31, 2023
Professional Services, Other Energy, Utilities, Alternative Energy, Energy, Finance, Senior, ASEAN, TTE, Cloud Peak Energy, Growth, Carbon, NYSE, Multimedia, Renewable energy, TotalEnergies

Peak Energy Investments Ltd. (“Peak Energy”), a platform dedicated to the development, ownership, and operation of renewable assets in Asia, today announced the appointments of Gavin Adda as Chief Executive Officer and Geoffrey Jahnke as Chief Operating Officer, effective November 1, 2023.

Key Points: 
  • Peak Energy Investments Ltd. (“Peak Energy”), a platform dedicated to the development, ownership, and operation of renewable assets in Asia, today announced the appointments of Gavin Adda as Chief Executive Officer and Geoffrey Jahnke as Chief Operating Officer, effective November 1, 2023.
  • Both join from TotalEnergies (NYSE: TTE) Renewables Asia, where Gavin previously served as CEO, and Geoffrey previously served as COO / CFO.
  • We are excited to have them on board and we look forward to seeing the results of their thoughtful stewardship of the platform’s expansion.”
    “I’m thrilled to be joining Peak Energy, especially at this exciting juncture in the platform’s growth,” said Gavin Adda, incoming Chief Executive Officer of Peak Energy.
  • I am excited to dive in alongside Gavin and the rest of the Peak Energy team as we work to create more sustainable futures, together.”

NeuraSignal’s NovaGuide™ Intelligent Ultrasound System Significantly Outperforms Standard of Care for Detecting Stroke-Associated Heart Defects

Retrieved on: 
Tuesday, October 10, 2023
Patent, Diagnosis, Esophagus, PFO, Physician, Edward Hines, Acquisition, Intelligence, TCD, Brain, RLS, Risk, Heart, Safety, Travel, LOS, TEE, Recurrence, TTE, Principal, Robotics, Service, Neurology, Pathology, Veterans Health Administration, Patient, Medical imaging, Pharmaceutical industry, Stroke

LOS ANGELES, Oct. 10, 2023 (GLOBE NEWSWIRE) -- NeuraSignal, a medical technology and data company specializing in the assessment and management of brain health, today announced the publication of positive results from the BUBL clinical study (#NCT04604015) supporting the safety and superior performance of its NovaGuide Intelligent Ultrasound system in detecting Right to Left Shunt (RLS) — often due to a patent foramen ovale (PFO) — in patients with acute ischemic stroke. The data, published in Stroke, show that the NovaGuide system detected RLS that TTE missed. Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.

Key Points: 
  • The data, published in Stroke , show that the NovaGuide system detected RLS that TTE missed.
  • Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.
  • “An accurate assessment for RLS is a critical part of evaluating patients with cryptogenic ischemic stroke.
  • The standard of care for PFO screening is TTE, an ultrasound-based approach in which the ultrasound transducer is moved across the chest to create an image of the heart.

Upland Community Approves Governance Vote to Make Utility Token ‘Spark’ Tradable on Ethereum

Retrieved on: 
Tuesday, October 17, 2023
Metaverse, EOS, Developer, TTE, Entrepreneurship, Ecosystem, Disability-adjusted life year, NFT, White paper, Silicon, Comment, Cryptocurrency, Ethereum, Spark

Upland , the leading web3 Metaverse Super App, announces its plans to make its in-game utility token Spark tradable on Ethereum following an overwhelming majority (87.25%) approval in a recent community governance vote.

Key Points: 
  • Upland , the leading web3 Metaverse Super App, announces its plans to make its in-game utility token Spark tradable on Ethereum following an overwhelming majority (87.25%) approval in a recent community governance vote.
  • Upland presented the Sparklet White Paper to the community to review in late September, which outlined the initiative to bridge the in-app token Spark to Ethereum where it will be mirrored and minted as the Sparklet token, equivalent to one-thousandth of Spark.
  • Current and future utility details along with tokenomics, Sparklet vesting schedules, implementation, and token distribution were also presented to the Upland community in the White Paper for comment ahead of the governance vote.
  • With the community approval of the Sparklet White Paper, Upland is now preparing the next steps to make Spark tradable outside of Upland via a Token Tradability Event (“TTE”), where Spark, a utility token on the EOS blockchain, will be mirrored by the Sparklet token on the Ethereum blockchain.

Study Confirms Ultromics' AI Can Improve HFpEF Detection Using a Single Echocardiogram View

Retrieved on: 
Monday, July 31, 2023
Mayo Clinic, Saint George, Education, Hospital, Survival, Eye, University Hospitals Cleveland Medical Center, Research, Heart failure with preserved ejection fraction, Doctor of Philosophy, Incidence, M.D, TTE, Patient, Data, Institutional review board, NHS foundation trust, ASE, Artificial intelligence, Heart failure, Diagnosis, Mortality, AI, FDA, Health, Society, American Society of Echocardiography, Disease, Medical device, Medical imaging, Pharmaceutical industry, Nursing

OXFORD, England, July 31, 2023 /PRNewswire/ -- Applying AI to a single apical four chamber (A4C) view echocardiogram provides accurate information to detect heart failure with preserved ejection fraction (HFpEF), according to research published today in JACC Advances.1

Key Points: 
  • Ultromics' EchoGo® Heart Failure accurately detected HFpEF and provided fewer non-diagnostic outputs than current clinical scores, using just the routinely acquired A4C view from a transthoracic echocardiographic (TTE).
  • As the first AI platform cleared to detect the condition, EchoGo® Heart Failure can fill a significant unmet need."
  • Ross Upton, PhD, CEO and Founder of Ultromics, said: "Our research demonstrates the tremendous potential of AI in revolutionizing the detection of HFpEF.
  • Automated Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction using Artificial Intelligence.

NextDecade Announces Positive Final Investment Decision on Rio Grande LNG Phase 1

Retrieved on: 
Wednesday, July 12, 2023
Professional Services, Other Energy, Environment, Oil, Gas, Energy, Finance, Investment, Special Protection Area, EPC, ENN, NTP, FERC, MTPA, TTE, NYSE, Bechtel, Port of Brownsville, Sidley Austin, Coal, Itochu, ExxonMobil, White, Shell, LLP, Kirkland & Ellis, Port, Multimedia, Latham & Watkins, History, Carbon, Phase 1, Natural gas, MUFG Bank, GIC, Partnership, Sale, FID, Global Infrastructure Partners, GIP, TotalEnergies, Financial services, Security (finance), Renewable energy, Mubadala Investment Company, Lower Rio Grande Valley, LNG

NextDecade Corporation (NextDecade, the Company) (NASDAQ: NEXT) is proud to announce it has made a positive final investment decision (FID) to construct the first three liquefaction trains (Phase 1) at the Company’s 27 million tonnes per annum (MTPA) Rio Grande LNG (RGLNG) export facility in Brownsville, Texas.

Key Points: 
  • NextDecade Corporation (NextDecade, the Company) (NASDAQ: NEXT) is proud to announce it has made a positive final investment decision (FID) to construct the first three liquefaction trains (Phase 1) at the Company’s 27 million tonnes per annum (MTPA) Rio Grande LNG (RGLNG) export facility in Brownsville, Texas.
  • The $18.4 billion project financing for RGLNG Phase 1, is the largest greenfield energy project financing in U.S. history and underscores the critical role that LNG and natural gas will continue to play in the global energy transition.
  • The Company believes these options with its partners will enable NextDecade to deliver the full FERC-approved five-train RGLNG project over time.
  • MUFG Bank, Ltd. acted as financial advisor to NextDecade in connection with the debt financing and Macquarie Capital (USA) Inc. acted as financial advisor to NextDecade in connection with the equity financing.

The CorVista® Analysis provides a supervised machine-learned algorithm to IDENTIFY PH patients with New Onset Symptoms

Retrieved on: 
Sunday, May 21, 2023
Research, Professional Services, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Data Analytics, Science, Cardiology, FDA, Health, Metadata, ATS, RHC, Cardiovascular disease, Multimedia, Federal, American Thoracic Society, Limited, TTE, Acquisition, PH, Diagnosis, Pulmonary hypertension, Breakthrough, Medical imaging, Pharmaceutical industry, Patient

This proof of concept showcases the effectiveness of a machine learned (ML) phase space electro-mechanical pulse wave analysis to identify pulmonary hypertension (PH) patients with new onset symptoms at the point-of-care.

Key Points: 
  • This proof of concept showcases the effectiveness of a machine learned (ML) phase space electro-mechanical pulse wave analysis to identify pulmonary hypertension (PH) patients with new onset symptoms at the point-of-care.
  • The measurements are used to identify PH patients with new onset symptoms.
  • The study enrolled consecutive patients across US-based healthcare centers who presented symptoms suggestive of PH.
  • “This advancement, when integrated into a point-of-care test, holds great promise for early PH detection within the clinical pathway.”
    Detailed results are available in the attached abstract from the ATS 2023 program: A Supervised Machine-learned Algorithm to IDENTIFY PH in Patients With New Onset Symptoms .

Cellebrite Enhances Guardian with Faster, First-to-Market Evidence Review Capabilities

Retrieved on: 
Wednesday, October 19, 2022
U.S. Securities and Exchange Commission, Web browser, Communication, SEC, Transport, Growth, Review, Failure, Workflow, TTE, Guardian, Solution, Organization, NASDAQ, Privacy, Cellebrite, Twitter, Annual report, Collection, Nasdaq, Private Securities Litigation Reform Act, Marketing, DI, GLOBE, Government, Digital, Digital intelligence, COVID-19, Compliance, Risk management

Cellebrite Guardian also allows agencies to use their resources more efficiently.

Key Points: 
  • Cellebrite Guardian also allows agencies to use their resources more efficiently.
  • Without the restraints of limited duration of storage and access to extractions, Cellebrite Guardian puts the customer at the center, allowing them to better address numerous evidence management challenges no matter how big the case or how long it takes.
  • Cellebrite Guardian is not only managing the critical relationship between investigator and examiner, but also ensuring that digital intelligence is immediately actionable regardless of hardware or skillset.
  • The faster review capabilities for Cellebrite Guardian are critical for accelerating the time to justice in any investigation, said Todd Bailey, Vice President and Head of Investigation and Evidence Management Solutions at Cellebrite.